Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Advanced Solid Tumors × durvalumab × Clear all

Phase

Status

Completed 5 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 14 Lung Neoplasms 4 Urinary Bladder Neoplasms 3 Small Cell Lung Carcinoma 3 Ovarian Neoplasms 3 Colorectal Neoplasms 3 Uterine Cervical Neoplasms 2 Triple Negative Breast Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Prostatic Neoplasms 2 Pancreatic Neoplasms 2 Neoplasms 2 Multiple Myeloma 2 Carcinoma, Transitional Cell 2 Breast Neoplasms 2 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Urothelial Cancer 1 Urinary Bladder Diseases 1 Thyroid Neoplasms 1 Thyroid Cancer, Papillary 1 Thrombocytosis 1 Testicular Neoplasms 1 Solid Tumors 1 Solid Tumor 1 Solid Cancer 1 Recurrence 1 Rectal Neoplasms 1 Radiation Pneumonitis 1 Primary Myelofibrosis 1

Interventions

Carboplatin 3 Docetaxel 2 Cisplatin 2 BMS-753493 2 zimberelimab 1 tislelizumab 1 spartalizumab 1 pembrolizumab 1 olaparib 1 liposomal doxorubicin 1 linifanib 1 lenvatinib 1 ixabepilone 1 durvalumab 1 avelumab 1 avdoralimab 1 adavosertib 1 Nivolumab 1 N-(2-fluoro-4-((2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)carbonylaminopyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 1 Maximum Tolerated Dose 1 Linoleic Acids, Conjugated 1 Lapatinib 1 Irinotecan 1 Ipilimumab 1 Injections 1 Ifosfamide 1 Gemcitabine 1 Fluorouracil 1 Doxorubicin 1 Dosage Forms 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03665129 2022-01-27

STELLAR-001

Innate Pharma

Phase 1 Terminated

Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡